Circio Holding ASA (OSE: CRNA), an Oslo-based biotechnology company developing circular RNA expression technology for gene and cell therapy, has announced a live investor webcast scheduled for 10:00am CET on Friday 27 November 2026. The update will cover pre-clinical circVec results, new in vivo proof-of-concept data for circVec in next-generation AAV capsids, and a summary of the company's presentations at ESGCT 2026. The webcast will also address the recently announced collaboration with Solid Biosciences, making this a significant touchpoint for investors tracking Circio's heart gene therapy programme and broader pipeline progress.

Key Points

  • Circio Holding ASA (OSE: CRNA / 0RIS), an Oslo-listed biotechnology company
  • Live webcast scheduled for 10:00am CET on 27 November 2026, covering R&D and corporate developments
  • New in vivo proof-of-concept data for circVec in next-generation AAV capsids to be presented, alongside ESGCT 2026 highlights
  • Investors should watch for detail on the Solid Biosciences collaboration and progress within the heart gene therapy programme

CEO and CTO to Present circVec Pre-Clinical Results and Heart Programme Advances

CEO Dr Erik D Wiklund will provide an overview of ongoing business development activities during the webcast, with particular focus on the recently announced collaboration with Solid Biosciences. CTO Dr Thomas B Hansen will present the latest circVec pre-clinical gene therapy results, encompassing the heart programme and new in vivo proof-of-concept data for circVec in next-generation AAV capsids. The session will also include a summary of Circio's oral presentation and two posters delivered at the European Society of Gene and Cell Therapy conference ESGCT 2026, reflecting the company's recent scientific activity.

circVec Platform Demonstrates 75-Fold RNA Half-Life Increase Over Conventional mRNA Systems

Circio's proprietary circVec platform is a modular genetic construct designed for efficient biogenesis of multifunctional circular RNA inside target cells. The company states the platform has demonstrated a 75-fold increased RNA half-life and up to 60-fold enhanced protein expression compared with conventional mRNA-based viral and non-viral vector systems. The platform has potential applications across genetic medicine, cell therapy, and chronic disease. R&D activities are conducted by wholly owned subsidiary Circio AB, based in Stockholm, Sweden, underscoring the company's dual operational presence across Norway and Sweden.

Solid Biosciences Collaboration Adds Strategic Weight to Circio's AAV Gene Therapy Pipeline

The recently announced collaboration with Solid Biosciences represents a notable development for Circio's pipeline strategy, and the upcoming webcast is expected to provide investors with additional context around its scope and objectives. The announcement does not disclose financial terms or milestone structures for this collaboration. Investors may be watching closely for any forward-looking commentary from management on how the partnership could accelerate the circVec platform's application within AAV-based gene therapies, particularly given the platform's stated performance advantages over existing vector systems.

Webcast Access Details and Presentation Materials for 27 November 2026

The webcast will be conducted in English via Microsoft Teams, with Meeting ID 345 519 158 255 488 1 and passcode g86R3cS9. Questions may be submitted in advance by email to CEO Erik D Wiklund or posed directly during the live session. Presentation materials will be published ahead of the event on 27 November 2026, and a recording will subsequently be made available on the Circio website. Investors seeking further information may contact the company directly through the contact details provided in the announcement.